Histological and genetic markers for non-small-cell lung cancer: Customizing treatment based on individual tumor biology

Pharmacology, Toxicology and Pharmaceutical Science

• DNA 100%
• Non Small Cell Lung Cancer 100%
• Neoplasm 100%
• Epidermal Growth Factor Receptor 100%
• Taxane 100%
• Clinical Trial 66%
• Ribonucleotide Reductase 66%
• Gemcitabine 66%
• Ribonucleotide 66%
• Cisplatin 33%
• Retrospective Study 33%
• Tolerability 33%
• Thymidylate Synthase 33%
• Biological Marker 33%
• Protein 33%
• Carcinogenicity 33%
• Protein Tyrosine Kinase 33%
• Cell Surface Receptor 33%
• Endonuclease 33%
• Tubulin 33%
• Combination Therapy 33%
• Enzymes 33%
• Monoclonal Antibody 33%
• Pemetrexed 33%
• Antimetabolite 33%
• Deoxyribonucleotide 33%
• Uracil 33%
• Purine 33%
• Electron Affinity 33%